NeuroKaire

What NeuroKaire does

NeuroKaire (legally GenetikaPlus Ltd., formerly operating as Genetika+) is an Israel-based precision medicine company founded in 2018 that develops an AI-powered 'brain-in-a-dish' platform to personalize treatment for depression and other central nervous system disorders. The core technology reprograms patient blood cells into induced pluripotent stem cells and differentiates them into frontal cortex neurons, which are then functionally screened against up to 70+ antidepressant candidates. Pharmacogenetic and neuroplasticity readouts are combined with the proprietary StemifAi AI engine to predict drug response and rank medications by likely effectiveness and tolerability. The company is led by CEO Dr. Talia Cohen Solal and CSO Dr. Daphna Laifenfeld, with a team of approximately 17 scientists and professionals and dual headquarters in Tel Aviv and Kearny, New Jersey.

The company operates two integrated product lines. BrightKaire, launched commercially in the United States in September 2025 following CLIA certification, is a blood-based diagnostic priced at $1,245 per patient ($550 for Medicare/Medicaid, HSA/FSA eligible) and delivered to ordering physicians via the NeuroKaire provider portal, with sample collection through Quest Diagnostics or Travalab at-home phlebotomy. PharmaKaire is the biopharma services platform offering neuronal assay data, biomarker discovery, patient stratification, and companion diagnostics development to pharmaceutical partners across the drug development lifecycle, supported by collaborations with Compass Pathways, NeuroSense Therapeutics, and Clexio Biosciences. The company maintains a proprietary Diverse Biobank of patient-derived neurons and access to large partner datasets including Maccabi's 100,000-patient cohort.

NeuroKaire has raised approximately $30 million in disclosed equity funding across multiple rounds led or participated in by GreyBird Ventures, Jumpspeed Ventures, Meron Capital, and Sapir Venture Partners, supplemented by up to €17.5 million from the European Commission's EIC Accelerator, BIRD Foundation grant participation, and Israel Innovation Authority support. The platform is validated through 13+ clinical and academic partnerships including Sheba Medical Center, Jefferson Health, the National Institute of Mental Health (NIMH), CAN-BIND, Maccabi Healthcare Services, and Rutgers New Jersey Medical School, and the company has received CE Mark, CLIA, CAP, HIPAA, and GDPR certifications supporting commercial operations across the US (49 of 50 states), Europe, and Israel.

Name

NeuroKaire

Legal name

GenetikaPlus Ltd.

Website

https://neurokaire.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

NeuroKaire is an Israeli precision medicine company that uses an AI-powered brain-in-a-dish platform to personalize depression treatment. Its BrightKaire blood test predicts patient-specific antidepressant response, while PharmaKaire provides biopharma partners with neuronal assays, biomarkers, and patient stratification services.

Ownership category

akta.pro rank

Product category

Precision Medicine Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG)

Keywords

• Precision medicine diagnostics
• Pharmacogenomic testing
• Antidepressant response prediction
• Neuronal drug screening
• CNS drug development

Headquarters

HQ city

Tel Aviv-yafo

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Diagnostic Testing (BrightKaire): NeuroKaire generates revenue through its BrightKaire blood test, a personalized mental health diagnostic that evaluates how a patient's neurons respond to antidepressants. Patients pay $1,245 USD for the test, with reduced out-of-pocket costs ($550) for Medicare/Medicaid patients. Tests are ordered by clinicians and results delivered to the prescribing physician.
2. Biopharma Drug Development Services (PharmaKaire): NeuroKaire provides drug discovery, development, and commercialization services to biopharma partners through its PharmaKaire platform. Services include target discovery, candidate screening, preclinical modeling, patient stratification, biomarker identification, companion diagnostics development, and market access strategies. Revenue from pharma partnerships supports the full drug development lifecycle collaboration.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

NeuroKaire operates two integrated product lines on its proprietary StemifAi AI platform. BrightKaire is a clinical blood-based diagnostic test that reprograms patient blood cells into patient-specific frontal cortex neurons and tests up to 70+ antidepressants to predict personalized treatment response, reducing antidepressant identification time from 12-18 months to approximately 2 months. PharmaKaire is a biopharma-facing drug development platform offering patient-derived neuronal assays, biomarker discovery, patient stratification, and companion diagnostics across the drug development lifecycle.

Product overview

NeuroKaire is a precision medicine company operating two integrated product lines built on its proprietary StemifAi platform. The core consumer/clinical product is BrightKaire — a blood-based diagnostic test that personalizes antidepressant selection by reprogramming patient stem cells into frontal cortex neurons and testing their response to antidepressants using AI. The biopharma-facing product is PharmaKaire — an end-to-end drug development platform offering patient-derived neuronal assays, biomarker discovery, and AI-powered patient stratification for clinical trials. Both products are powered by StemifAi, NeuroKaire's AI-driven drug response prediction engine that combines pharmacogenetics with neuroplasticity measurements from patient-derived neurons.

Differentiator

Problem solved

Functional benefit

Brands

• PharmaKaire: Precision medicine and drug development tools for biopharma partners, offering brain-in-a-dish platform and AI-driven drug response prediction technology across the drug development lifecycle.
• BrightKaire

Products and services

• BrightKaire Advanced blood-based diagnostic test that personalizes antidepressant treatment by reprogramming patient blood cells into stem cells and then into frontal cortex neurons to test how each patient's brain responds to up to 70 antidepressants. Delivers a ranked report predicting medication effectiveness and tolerability within approximately 12 weeks, reducing the treatment identification timeline from 12-18 months to two months. Targeted at clinicians treating patients with major depressive disorder and self-paying patients seeking personalized treatment guidance.
• PharmaKaire Precision medicine and drug development platform for biopharma partners, offering brain-in-a-dish neuronal assay data integrated across the drug development lifecycle from target discovery and preclinical validation through Phase I/II/III trials and post-marketing. Supports patient stratification, biomarker identification, companion diagnostics, and market access strategies using patient-derived neurons and AI-driven analytics. Targeted at pharmaceutical and biotech companies developing CNS drugs.

Quantifiable outcome

• Treatment identification timeline reduced from 12-18 months to approximately 2 months
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Compass PathwayscoreStrategic or Co-development Partner · 30 October 2025NeuroKaire entered an R&D collaboration with Compass Pathways to study the effects of psychedelic compounds on neurons using AI-powered analysis. The study aims to develop personalized treatments for depression by exploring cellular mechanisms and communication between neurons, combining NeuroKaire's brain-in-a-dish platform with Compass Pathways' psychedelic compound research.
• NeuroSense TherapeuticscoreStrategic or Co-development PartnerPrecision medicine collaboration beginning with NeuroSense's ongoing Phase 2 clinical trial in Alzheimer's disease. NeuroKaire uses its patient-derived neurons and neuronal plasticity markers platform to characterize drug response in Alzheimer's patient-derived neurons, supporting NeuroSense's drug development pipeline.
• Clexio BiosciencesminorStrategic or Co-development PartnerPartnership using NeuroKaire's proprietary antidepressant screening platform to support Clexio's drug development programs. Collaboration involves profiling drug response mechanisms and patient sub-populations through readouts from NeuroKaire's biobank of patient-derived neurons.
• Sheba Medical CentercoreStrategic or Co-development PartnerFeasibility study led by Dr. Revital Amiaz to investigate the potential of NeuroKaire's blood test to predict SSRI treatment outcomes in major depression patients. Sheba is NeuroKaire's flagship clinical trial partner in Israel.
• National Institute of Mental Health (NIMH)coreStrategic or Co-development PartnerClinical trial collaboration using patient-derived neurons to study antidepressant response mechanisms. NIMH provides access to STAR*D study patient samples (LCLs from NIMH Repository and Genomics Resource) and supports research into biomarkers for depression treatment response.
• Jefferson Health / Thomas Jefferson UniversitycoreStrategic or Co-development PartnerUS clinical trial partner for therapeutic biomarkers of depression study led by Dr. Karin Borgmann-Winter and Dr. Chang-Gyu Hahn. Study aims to identify biomarkers associated with antidepressant responsiveness and resistance in MDD patients using patient-derived neurons.
• Maccabi Healthcare Services / KSM Research & Innovation CentercoreStrategic or Co-development PartnerRetrospective study led by Dr. Tal Patalon developing and validating a machine learning model for antidepressant treatment personalization using Maccabi's dataset of 90,000 depression patients and 10,000 controls. Supports AI-driven decision support system development.
• CAN-BIND ConsortiumcoreStrategic or Co-development PartnerCollaboration as part of the CAN-BIND (Canadian Biomarker Integration Network in Depression) consortium. Joint study with Prof. Jonathan Rabinowitz developing machine learning-based classification models to predict antidepressant response using comprehensive patient data including genomic, genetic, and proteomic profiles.
• Clalit Health ServicesminorStrategic or Co-development PartnerResearch partnership with Clalit's innovation arm to study blood-derived biomarkers for predicting antidepressant response in major depression patients, generating neuronal cells from MDD patients to establish NeuroKaire's MDD disease model.
• Mazor Mental Health Medical CenterminorStrategic or Co-development PartnerResearch partnership led by Prof. Alon Shamir exploring morphological, molecular, and functional differences between microglia-like cells and neurons derived from schizophrenic patients and healthy individuals, evaluating antipsychotic treatment effects.
• Geha Mental Health CenterminorStrategic or Co-development PartnerClinical study partner for generating neuronal cells from MDD patients and establishing NeuroKaire's major depressive disorder disease model, led by Dr. Tom Fruchtman-Steinbok.
• Rutgers New Jersey Medical SchoolminorStrategic or Co-development PartnerAcademic research partner within NeuroKaire's precision medicine network, contributing to collaborative research in psychiatric neuroscience and depression treatment.
• MassChallengeminorOthersNeuroKaire participated in MassChallenge accelerator program as a female-led startup, receiving funding and growth support through the accelerator. The company credits MassChallenge as helping it grow and gain funding.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Myriad Genetics (GeneSight): Myriad's GeneSight Psychotropic test is the market-leading pharmacogenomic test for antidepressant and psychiatric medication selection. It is the most direct competitive analogue to BrightKaire, addressing the same clinical decision point with a different (genetic proxy) methodology and established US reimbursement.
• Genomind: Genomind sells the Genecept Assay, a pharmacogenomic test guiding psychotropic prescribing. It targets the same prescribers and patient population as NeuroKaire and represents one of the closest head-to-head competitors in PGx-driven depression treatment selection.
• Alto Neuroscience: Alto Neuroscience is a clinical-stage precision psychiatry company using biomarker-driven patient stratification to develop CNS drugs. It shares NeuroKaire's biomarker-plus-AI approach to depression, albeit from a drug-development rather than diagnostic-testing angle, making it a strong adjacent direct peer.

Broad incumbents

• Neumora Therapeutics: Neumora is a well-capitalized CNS precision medicine company developing neuroscience therapeutics informed by patient stratification. While a drug developer rather than a diagnostic, its data-driven approach to CNS treatment is highly comparable in mission and end customer (psychiatrists).
• Sage Therapeutics: Sage Therapeutics develops novel CNS therapies including Zurzuvae (postpartum depression) and zuranolone. Comparable to NeuroKaire in CNS focus and depression treatment; Sage is a biopharma incumbent that may also be a potential PharmaKaire partner or competitor for clinical-trial patient stratification.
• Acadia Pharmaceuticals: Acadia is a CNS-focused biopharma with commercial products in Parkinson's psychosis and Rett syndrome, and an active pipeline in CNS adjacencies. It is a comparable incumbent in CNS specialty pharma and a plausible PharmaKaire counterpart for biomarker and patient-stratification services.
• Karuna Therapeutics: Karuna developed xanomeline-trospium (Cobenfy) for schizophrenia, recently approved and now part of BMS. Comparable to NeuroKaire in CNS precision and treatment-resistant psychiatric indications, and is illustrative of the exit-value pathway for biomarker-enabled CNS companies.

Emerging players

• Praxis Precision Medicines: Praxis develops precision medicines for CNS disorders including depression, using genetic and biomarker insights to guide therapeutic development. Comparable to NeuroKaire in CNS focus and precision-medicine philosophy, though operating on the therapeutic side rather than the diagnostic/services side.
• Compass Pathways: Compass Pathways is developing psilocybin therapy for treatment-resistant depression. NeuroKaire is a current R&D partner, but Compass is also thematically adjacent — both target precision treatment of refractory depression using novel mechanisms, and both rely on biomarker identification of likely responders.
• Taliaz Health: Taliaz Health is an Israel-based AI mental health company offering decision-support tools for antidepressant prescribing using predictive analytics. Comparable in geographic origin, therapeutic focus, and AI-driven treatment-personalization value proposition, though using clinical/genetic data rather than patient-derived neurons.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neurokaire

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroKaire